Stock Research: Cogent Biosciences

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Cogent Biosciences

NSQ:COGT US19240Q2012
43
  • Value
    65
  • Growth
    58
  • Safety
    Safety
    13
  • Combined
    44
  • Sentiment
    47
  • 360° View
    360° View
    43
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

ANALYSIS: With an Obermatt 360° View of 51 (better than 51% compared with alternatives), overall professional sentiment and financial characteristics for the stock Cogent Biosciences are above average. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Cogent Biosciences. The consolidated Value Rank has an attractive rank of 71, which means that the share price of Cogent Biosciences is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 71% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 51, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 73. But the company’s financing is risky with a Safety rank of 13. This means 87% of comparable companies have a safer financing structure than Cogent Biosciences. ...read more

more
Index
NASDAQ
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 26-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
65 n/a n/a n/a
Growth
58 n/a n/a n/a
Safety
Safety
13 n/a n/a n/a
Sentiment
47 n/a n/a n/a
360° View
360° View
43 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
19 n/a n/a n/a
Opinions Change
18 n/a n/a n/a
Pro Holdings
n/a n/a n/a n/a
Market Pulse
68 n/a n/a n/a
Sentiment
47 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
65 n/a n/a n/a
Growth
58 n/a n/a n/a
Safety Safety
13 n/a n/a n/a
Combined
44 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
37 n/a n/a n/a
Price vs. Earnings (P/E)
82 n/a n/a n/a
Price vs. Book (P/B)
7 n/a n/a n/a
Dividend Yield
n/a n/a n/a n/a
Value
65 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
91 n/a n/a n/a
Profit Growth
10 n/a n/a n/a
Capital Growth
55 n/a n/a n/a
Stock Returns
94 n/a n/a n/a
Growth
58 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
15 n/a n/a n/a
Refinancing
49 n/a n/a n/a
Liquidity
31 n/a n/a n/a
Safety Safety
13 n/a n/a n/a

Similar Stocks

Discover high‑ranked alternatives to Cogent Biosciences and broaden your portfolio horizons.

Toll Brothers

NYQ:TOL
Country: USA
Industry: Homebuilding
Size: X-Large
Full Stock Analysis

Aramark

NYQ:ARMK
Country: USA
Industry: Restaurants
Size: X-Large
Full Stock Analysis

Keurig Dr Pepper

NSQ:KDP
Country: USA
Industry: Soft Drinks
Size: X-Large
Full Stock Analysis

Regeneron Pharmaceuticals

NSQ:REGN
Country: USA
Industry: Biotechnology
Size: Large
Full Stock Analysis

Frequently Asked
Questions

This is a high-quality, high-growth stock with positive sentiment. However, the financing is on the riskier side. It is best for a growth-focused investor willing to accept higher financial risk for potentially higher shareholder returns.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: